Dr. Lal Pathlabs rises as its arm acquires remaining 30% stake in Centrapath Labs
Mumbai, October 14 (Udaipur Kiran): Dr. Lal Pathlabs is currently trading at Rs. 1928.20, up by 16.70 points or 0.87% from its previous closing of Rs. 1911.50 on the BSE.
The scrip opened at Rs. 1909.00 and has touched a high and low of Rs. 1932.00 and Rs. 1884.05 respectively. So far 10994 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 2035.00 on 16-Sep-2026 and a 52 week low of Rs. 1272.00 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 2002.85 and Rs. 1884.05 respectively. The current market cap of the company is Rs. 32314.25 crore.
The promoters holding in the company stood at 53.19%, while Institutions and Non-Institutions held 38.82% and 7.99% respectively.
Dr. Lal Pathlabs’ Wholly Owned Subsidiary– PathLabs Unifiers (PUPL) has acquired the remaining 30% equity stake in Centrapath Labs (CPL), a Subsidiary of PUPL, on October 13, 2026. Pursuant to the aforesaid acquisition, CPL has become a Wholly Owned Subsidiary of PUPL.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
